{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "TNDM",
  "name": "Tandem Diabetes Care, Inc.",
  "url": "https://orbyd.app/dossiers/TNDM/",
  "json_url": "https://orbyd.app/dossiers/TNDM.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Beaten-down insulin-pump turnaround; the whole re-rate hinges on the tubeless Mobi (\"Toby\") 510(k) — planned for a Q2 filing but still unconfirmed after the quarter closed 2026-06-30 — plus margins scaling toward a ~60% Q4 exit. Shares bounced off the floor to ~$17 but sell-side stays neutral (Mizuho cut to $20). The 2026-08-06 Q2 print is the next binary.",
  "invalidation_trigger": "A weekly close below $14 forfeits the July recovery base and re-opens the downtrend toward the $9.98 52-week floor. Secondary: the tubeless Mobi 510(k) still unconfirmed at the 2026-08-06 Q2 print, a FY2026 sales guide cut below $1.065B, or diabetes-AID leadership staying with Insulet's Omnipod.",
  "catalyst_date": "2026-08-06",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "2026-07-01: launched t:slim X2 Control-IQ+ integration with Abbott FreeStyle Libre 3 Plus in UK, Switzerland, Sweden, Finland, Italy; more EU markets guided later 2026.",
    "Competitive flank: Insulet Omnipod 5 (patch-pump leader, direct tubeless-Mobi competitor), Beta Bionics (Dexcom-paired patch, Mint ~2027), Medtronic MiniMed patch pump. Tandem arrives late to tubeless.",
    "Distribution lever: 7-day infusion set FDA-cleared and rolling out 2026; pharmacy-channel / PayGo shift (Citi 2026 event) widening reach beyond DME.",
    "Q2 CY2026 earnings confirmed for 2026-08-06 after market close (call 4:30pm ET) — binary print; avoid fresh entries into it.",
    "Whole thesis hinges on tubeless Mobi 'Toby': 510(k) planned for Q2-2026 filing (quarter closed 2026-06-30), no submission press release confirmed as of 2026-07-25; clearance guided H2-2026, phased rollout after. Filing confirmation or slip is the near-term de-risk/risk signal — likely resolved at/before the Aug 6 call.",
    "Value-trap structure improving to a basing attempt: ~$17.12 on 2026-07-25 (up from ~$15.3 early July, +4.9% on 2026-07-17 to $17.07), ~1x sales, ~$1.2B cap, still lower-middle of the $9.98–$29.65 range. Needs a base plus MA reclaim before it is a momentum setup.",
    "Sell-side neutral and cutting: Mizuho Neutral $20 (from $24, 2026-07-15), Goldman Hold $21, Deutsche Bank Hold $15.50 (2026-06-23), Wells Fargo Overweight $27; average ~$20. Same 2026-06-23 session Insulet got a bullish top-5 initiation — market preferring the incumbent.",
    "FY2026 guide (reaffirmed at Q1 print 2026-05-07): sales $1.065–1.085B, gross margin 56–57% (~60% Q4 exit, ~65% longer-term), adj EBITDA margin 5–6%. Q1 sales $247.2M +5% YoY, non-GAAP EPS -$0.30, record >29,000 pumps.",
    "Competitive flank: Insulet Omnipod 5 (patch-pump leader, direct tubeless-Mobi competitor), Beta Bionics (Dexcom-paired patch, Mint ~2027), Medtronic MiniMed patch."
  ],
  "body_markdown": "## Current Thesis\nTandem is a beaten-down insulin-pump turnaround where the entire re-rate rests on one leg: the tubeless Mobi (cartridge nicknamed \"Toby\"), a 510(k) planned for a Q2 2026 filing that is still unconfirmed after the quarter closed 2026-06-30, plus gross margin scaling from 56–57% toward a ~60% Q4 exit. Shares changed hands near $17.12 on 2026-07-25, up from roughly $15.3–$15.5 in early July after a +4.9% session on 2026-07-17 to $17.07 — a bounce off the floor, not a breakout, still sitting in the lower-middle of the $9.98–$29.65 52-week range. The market has not underwritten the story: Mizuho cut to Neutral $20 (from $24) on 2026-07-15, Goldman carries Hold at $21, Deutsche Bank Hold at $15.50, and the average target near $20 leaves thin upside from spot. A ~1x-sales multiple is cheap, but cheap on a name whose only near-term catalyst is an unsubmitted device is a value trap. The 2026-08-06 Q2 print is the next binary, and it lands with the Mobi filing still unproven.\n\n## Bull Case\n- Q1 CY2026 (reported 2026-05-07): worldwide sales $247.2M, +5% YoY, beat the ~$245.2M consensus; record quarterly shipments above 29,000 pumps; non-GAAP EPS -$0.30 vs -$0.45 expected — an operational beat off the 2025 \"year of transformation.\"\n- Margin inflection: FY2026 gross margin guided 56–57% with a ~60% Q4 exit and a longer-term ~65% target; management flagged a record ~58% quarterly margin at a recent investor conference, with adjusted EBITDA margin of 5–6%.\n- Tubeless Mobi \"Toby\": 510(k) planned for Q2 2026 filing, clearance guided H2 2026, phased rollout after — pitched as the first tubed/tubeless hybrid on one platform with extended (7-day) wear, compatible with existing Mobi pumps, the product that lets Tandem attack Insulet's patch-pump turf.\n- Distribution widening: management is leaning into a pharmacy-channel / PayGo model flagged at the recent conference, broadening reach beyond the traditional DME channel; the 7-day infusion set is FDA-cleared and rolling out in 2026.\n- 2026-07-01: launched t:slim X2 Control-IQ+ integration with Abbott's FreeStyle Libre 3 Plus (15-day-wear sensor) across five international markets (UK, Switzerland, Sweden, Finland, Italy), with more European launches guided later in 2026 — a live international AID growth lever.\n- FY2026 sales guide of $1.065–1.085B was reaffirmed at the Q1 print; Wells Fargo's Overweight $27 is the bull anchor in a split sell-side.\n\n## Bear Case\n- Sell-side is neutral-to-negative and still cutting: Mizuho to $20 Neutral (from $24, 2026-07-15), Goldman Hold $21, Deutsche Bank Hold $15.50 (2026-06-23, an 8.2x 2027 EV/EBITDA target); the average target near $20 sits only marginally above ~$17 spot.\n- The re-rate rests on a device that has not been confirmed submitted: the Q2 target quarter closed 2026-06-30 and no filing press release had landed by 2026-07-25. Any slip of the filing or the H2 2026 clearance removes the only near-term catalyst.\n- Competitive vise: Insulet's Omnipod 5 owns the patch-pump category, Beta Bionics is pairing with Dexcom and pushing a Mint follow-on around 2027, and Medtronic's MiniMed patch is planned. On the same 2026-06-23 session TNDM drew a Hold, Insulet landed a bullish top-five initiation — capital favors the incumbent.\n- Growth is pedestrian and the P&L still red: +5% YoY revenue with a -$0.30 non-GAAP Q1 loss is not enough to carry the multiple unless the Mobi launch and the margin ramp both land.\n- The July bounce runs straight into a binary print; buying the move ahead of 2026-08-06 is a bet on guidance, not a confirmed setup.\n\n## Setup & Price Structure\n- ~$17.12 on 2026-07-25, up from roughly $15.3–$15.5 in early July; +4.9% on 2026-07-17 to $17.07. Market cap ~$1.2B, ~1x sales.\n- 52-week range $9.98–$29.65 — price is lower-middle, well below the high, and the May-beat spike from earlier in the year had been fully retraced before this bounce.\n- The move reclaimed the mid-$15 zone (near the Deutsche Bank Hold target) but has not broken out; it stalls below the ~$20 average analyst target and far under $29.65.\n- Structure has improved from rolled-over to a basing attempt, yet there is no clean base plus moving-average uptrend to call it a momentum setup — and the base is untested through an earnings print.\n\n## Catalyst Calendar (next 30 days)\n\n- 2026-08-06 (after close, call 4:30pm ET): Q2 CY2026 results — binary. Watch for confirmation of the Mobi 510(k) submission, reaffirmation of the ~60% Q4 margin exit, and any FY2026 guide revision off the $1.065–1.085B range.\n- Ongoing 2026: additional European Control-IQ+ / FreeStyle Libre 3 Plus market launches beyond the initial five.\n\n## Elapsed catalysts\n\n- July–August 2026: Mobi tubeless \"Toby\" 510(k) submission press-release watch — the Q2 target quarter closed 2026-06-30, so a confirmation (or a stated slip) is the near-term de-risk/risk trigger, likely resolved at or before the Aug 6 call. *(passed 33d ago)*\n\n## What Would Change Our Mind\n- A confirmed Mobi 510(k) submission plus an Aug 6 print showing the ~60% Q4 margin exit on track and a reaffirmed-or-raised FY guide would give the turnaround a real catalyst; a weekly close back above the ~$20 analyst-target shelf on that would flip the read from basing to trend and warrant re-grading conviction upward.\n- Against the thesis: a weekly close below $14 forfeits the July recovery base and re-opens the downtrend toward the $9.98 floor; a filing slip past the Q2 target, or a sales guide cut below $1.065B, or diabetes-AID leadership staying entrenched with Insulet's Omnipod, confirms the value trap.\n\n## Correlation Notes\n- Moves with the diabetes-tech / automated-insulin-delivery complex: Insulet (PODD, patch-pump leader and the direct Mobi competitor), Dexcom (DXCM, CGM partner and Beta Bionics ally), Abbott (ABT, FreeStyle Libre partner), Medtronic (MDT, MiniMed).\n- Reads inversely to Insulet on the patch-pump share narrative — the 2026-06-23 Insulet initiation against a TNDM Hold frames the pair trade cleanly.\n- Small-cap medtech beta (~$1.2B cap, non-GAAP loss-making) makes it sensitive to rate moves and risk appetite, amplifying single-stock catalyst risk into the Aug 6 print.",
  "first_seen": "2026-06-17",
  "last_analyzed": "2026-07-25T08:42:27+00:00",
  "last_synthesized": "2026-07-25",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}